Physician profile
Matthew P Abdel
NPI 1245437128
$3,103,502.59
in general payments reported to CMS, 2019-2025
12 companies · $677K in 2025
The $677K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168K · 2020: $216K · 2021: $423K · 2022: $454K · 2023: $559K · 2024: $606K · 2025: $677K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.8M · Travel and Lodging: $60K · Consulting Fee: $13K · Food and Beverage: $7,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,761,340.08 |
| Travel and Lodging | $59,970.92 |
| Consulting Fee | $13,418.20 |
| Food and Beverage | $7,855.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,077,545.52 | 2019-2025 | Accolade, Mako, Trident |
| Osteoremedies, LLC | $24,596.24 | 2022-2025 | Biowash Surgical Irrigation, Remedy Poly+Plus Tibial Spacer, Biobrush |
| Foundation Medical, LLC | $421.47 | 2025 | |
| Becton, Dickinson and Company | $147.21 | 2022 | |
| Smith+Nephew, INC. | $133.24 | 2019 | |
| Medical Device Business Services, INC. | $132.71 | 2021-2023 | Attune |
| Horizon Therapeutics Plc | $109.04 | 2019 | |
| Depuy Synthes Sales INC. | $105.95 | 2019 | |
| Arthrex, INC. | $97.76 | 2025 | |
| Encore Medical, Lp | $96.23 | 2021 | |
| Heron Therapeutics, INC. | $62.45 | 2025 | Zynrelef |
| Total Joint Orthopedics, INC. | $54.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Abdel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.